The advent of next-generation nanocarriers represents a pivotal advancement in precision antitumor therapy, transitioning from rudimentary passive targeting mechanisms reliant on the enhanced permeability and retention (EPR) effect to sophisticated intelligent systems that respond dynamically to tumor-specific stimuli, thereby optimizing drug delivery, minimizing systemic toxicity, and enhancing therapeutic efficacy [1]. Traditional chemotherapy, while effective in disrupting cellular processes such as DNA replication and mitosis, often suffers from nonspecific distribution, leading to severe adverse effects including cardiotoxicity, nephrotoxicity, and neurotoxicity, as well as the emergence of multidrug resistance through mechanisms like efflux pump overexpression and defective apoptotic pathways [2]. In contrast, nanocarriers—engineered at the nanoscale (typically 10–200 nm)—offer a platform for controlled release, improved pharmacokinetics, and targeted accumulation within the tumor microenvironment, which is characterized by hypoxia, acidosis (pH 6.5–6.9), elevated interstitial fluid pressure, and aberrant angiogenesis [3]. The EPR effect, first conceptualized by Matsumura and Maeda in 1986, exploits the leaky vasculature of tumors (with endothelial gaps up to 400–800 nm) and impaired lymphatic drainage to facilitate passive extravasation of nanocarriers, achieving up to 10–50-fold higher concentrations in tumor tissues compared to normal organs, as demonstrated in preclinical models of breast and colorectal cancers [4]. However, limitations such as heterogeneous tumor permeability and off-target accumulation in reticuloendothelial system organs like the liver and spleen have prompted the development of active targeting strategies, where surface functionalization with ligands (e.g., antibodies, peptides, or aptamers) enables specific binding to overexpressed receptors such as folate receptor alpha or epidermal growth factor receptor (EGFR), resulting in enhanced cellular internalization via receptor-mediated endocytosis and up to 5–10 times greater intratumoral drug levels [5].

Further evolution into intelligent responsive nanocarriers incorporates stimuli-sensitive linkages (e.g., pH-cleavable hydrazones or enzyme-degradable peptides) that trigger drug release in response to endogenous cues like low pH, high glutathione concentrations (up to 10 mM in cytosol versus 2–20 μM extracellularly), or exogenous stimuli such as ultrasound or magnetic fields, thereby achieving spatiotemporal control and overcoming barriers like endosomal escape, as evidenced by studies showing 80–90% drug release in acidic environments versus < 20% at physiological pH [6]. This paradigm shift is underscored by the approval of over 50 nanomedicines by regulatory bodies like the FDA and EMA, including liposomal doxorubicin (Doxil^®) and albumin-bound paclitaxel (Abraxane^®), which have extended progression-free survival (PFS) in metastatic breast cancer patients by 3–6 months while reducing cardiotoxicity by 50–70% [7]. Nonetheless, challenges persist in clinical translation, including batch-to-batch variability, immune recognition leading to accelerated blood clearance, and the need for personalized approaches accounting for interpatient tumor heterogeneity, as highlighted in recent meta-analyses of phase III trials showing only 0.7–13.5% of administered nanoparticles reaching tumors [8]. Future directions emphasize hybrid nanocarriers combining multiple modalities, such as photothermal therapy with chemotherapy, and integration with immunotherapy to elicit durable antitumor immune responses, potentially increasing overall survival rates in advanced malignancies from 20–30% to over 50%, as projected in ongoing trials [9]. The passive accumulation of nanocarriers through the EPR effect is depicted schematically in Figure 1, highlighting leaky tumor vasculature and impaired lymphatic drainage that enable nanoparticle retention.

Despite the advantages of EPR, passive targeting remains highly variable across tumors and between patients. Human tumors often show reduced vascular leakiness compared to highly vascularized murine xenografts, leading to inconsistent nanocarrier accumulation [9]. Dense stromal structures, elevated interstitial fluid pressure, and heterogeneous vessel perfusion can limit nanoparticle transport, resulting in delivery efficiencies as low as 0.7–5% of the injected dose in certain solid tumors [10]. This strategy circumvents the need for active ligands, relying instead on nanocarrier physicochemical properties like size (optimal 50–150 nm to evade renal clearance < 10 nm and splenic sequestration > 200 nm), near-neutral surface charge (zeta potential –10 to +10 mV to minimize opsonization and macrophage uptake), and polyethylene glycol (PEG) coating for stealth properties that extend circulation half-life from minutes to 12–24 hours, thereby enhancing bioavailability and reducing peak plasma concentrations that cause toxicity in conventional formulations [11]. For instance, PEGylated liposomal doxorubicin exhibits a 16-fold increase in tumor exposure compared to free drug, with area under the curve (AUC) values of 590 μg·h/mL versus 36 μg·h/mL, leading to improved response rates (20–40%) in ovarian cancer patients while decreasing the incidence of hand-foot syndrome from 37% to 9% [12].

Quantitative studies using positron emission tomography (PET) with 89Zr-labeled nanocarriers have confirmed EPR-mediated accumulation, revealing intratumoral heterogeneity where vascularized peripheries accumulate 2–3 times more than necrotic cores, underscoring the need for complementary strategies to address penetration barriers imposed by elevated interstitial fluid pressure (10–40 mmHg in tumors versus 0–3 mmHg in normal tissues) [13]. Despite successes like nab-paclitaxel, which exploits albumin transport pathways for enhanced tumor uptake (up to 33% higher intratumoral paclitaxel levels), passive targeting faces challenges in hypopermeable tumors such as pancreatic ductal adenocarcinoma, where desmoplastic stroma limits diffusion, resulting in only 1–5% delivery efficiency; moreover, interspecies differences in EPR magnitude (higher in xenografts than autochthonous models) complicate translation, as evidenced by phase II trials showing modest improvements in overall survival (8.5 vs. 6.7 months) [14]. Several biological barriers further reduce the predictability of passive targeting. Nanocarriers may become sequestered by the reticuloendothelial system, particularly in the liver and spleen, limiting the fraction that reaches tumors. In addition, hypopermeable or fibrotic tumors such as pancreatic ductal adenocarcinoma exhibit tightly packed extracellular matrices, which restrict nanoparticle diffusion even after extravasation. As a result, drug concentrations are often higher at the tumor periphery than in deeper regions, reducing therapeutic efficacy in poorly perfused areas [15].

Recent engineering strategies aim to improve the uniformity and depth of passive nanoparticle penetration. Size-shrinkable nanocarriers that degrade from ~100 nm to < 20 nm in protease-rich microenvironments have shown improved movement through dense tumor tissue. Similarly, vascular normalization agents such as anti-VEGF antibodies can transiently lower interstitial pressure and enhance nanocarrier distribution by improving vessel function [16]. These approaches partially overcome the physical obstacles associated with exclusive reliance on the EPR effect. Figure 2 provides a side-by-side comparison demonstrating how active targeting builds upon passive accumulation by enabling selective cellular uptake through receptor-mediated interactions.

Active targeting enhances nanocarrier specificity by conjugating ligands such as monoclonal antibodies, antibody fragments (e.g., scFv), peptides [e.g., arginine-glycine-aspartic acid (RGD) for αvβ3 integrins], aptamers, or small molecules (e.g., folate) to the surface, facilitating receptor-mediated endocytosis and achieving 3–10-fold higher intracellular drug concentrations compared to passive counterparts, particularly in tumors overexpressing targets like human epidermal growth factor receptor 2 (HER2) (up to 10⁶ receptors/cell in breast cancer) or prostate-specific membrane antigen (PSMA) in prostate cancer [17]. Ligand density optimization (typically 0.5–2% of surface area) balances avidity (multivalent binding increases affinity by 10–100-fold) with stealth properties, as excessive modification can trigger immune clearance via anti-PEG antibodies, reducing circulation time by 50–70%; for example, trastuzumab-conjugated liposomes targeting HER2 demonstrate 4-fold greater uptake in SK-BR-3 cells (IC50 0.1 μg/mL vs. 0.4 μg/mL for non-targeted), translating to prolonged median survival in xenograft models (42 vs. 28 days) [18]. Quantitative biodistribution analyses using fluorescence resonance energy transfer (FRET) reveal that active targeting shifts accumulation from 5–10% passive to 15–25% active in tumor tissues, with reduced off-target in liver (from 40% to 20% of dose), as seen in anti-EGFR cetuximab-nanoparticles for glioblastoma, where blood-brain barrier crossing is facilitated by transferrin receptor shuttling, achieving 2–3-fold higher glioma penetration [19].

Challenges include antigen heterogeneity (e.g., only 60–80% of tumors express sufficient levels), ligand shedding, and endosomal entrapment (pH 5.5–6.0 triggers lysosomal degradation, releasing < 30% payload), addressed by incorporating pH-sensitive fusogenic peptides that enhance cytosolic escape by 50–80% [20]. Clinical trials of active-targeted nanocarriers, such as MM-302 (HER2-targeted liposomal doxorubicin), showed improved objective response rates (11% vs. 0% in controls) in phase II studies for advanced breast cancer, though PFS gains were modest (7.6 vs. 5.5 months) due to accelerated clearance in PEG-immunized patients [21]. Dual-ligand strategies, like RGD and transferrin co-functionalized micelles, synergize passive EPR with active uptake, yielding 5–7-fold efficacy in multidrug-resistant models by bypassing P-glycoprotein efflux (intracellular doxorubicin 2.5 μM vs. 0.5 μM) [22]. Future refinements involve stimuli-cleavable linkers [e.g., matrix metalloproteinase-2 (MMP2)-sensitive peptides] that unmask ligands in the tumor microenvironment, mitigating peripheral binding and extending half-life by 2–3-fold, as validated in orthotopic pancreatic cancer models with 90% tumor growth inhibition versus 50% for static ligands [23]. Thus, active targeting refines precision antitumor therapy, potentially increasing therapeutic windows by 5–10-fold, but requires patient stratification via companion diagnostics to match ligand-receptor profiles for optimal outcomes [24].

Drug release behavior represents one of the most critical determinants of nanocarrier performance in antitumor therapy, as it directly governs the spatiotemporal availability of therapeutics within the tumor microenvironment [25]. Broadly, nanocarriers exhibit several distinct release patterns—including burst release, diffusion-controlled release, erosion/degradation-controlled release, and stimuli-responsive (on-demand) release—each contributing unique advantages and limitations depending on the pathological context. Burst release refers to rapid initial drug liberation due to surface-adsorbed molecules, offering immediate therapeutic levels but posing risks of systemic toxicity [26]. Diffusion-controlled release enables sustained delivery as the drug permeates through the nanomatrix, supporting chronic dosing but often limited by slow penetration in poorly vascularized tumors [27]. Erosion or degradation-controlled release relies on hydrolytic or enzymatic breakdown of the carrier [e.g., poly(lactic-co-glycolic acid) (PLGA), gelatin], providing predictable kinetics and high stability, though degradation rates may vary across tumor phenotypes. In contrast, stimuli-responsive release—triggered by pH, redox gradients, enzymes, hypoxia, heat, ultrasound, or light—offers highly precise, on-demand delivery that maximizes intratumoral concentration while minimizing off-target exposure [27]. The merits of these advanced release patterns include enhanced therapeutic index, reduced systemic toxicity, improved penetration, and compatibility with combination therapy. However, challenges persist, such as variability of tumor microenvironmental triggers, premature activation in inflamed tissues, and manufacturing complexity [28]. These release mechanisms underpin a wide range of clinical applications, from sustained chemotherapeutic infusion to gene silencing, immunomodulation, and synergistic multimodal therapies. The following subsections illustrate representative examples of these release patterns, demonstrating how advanced nanocarrier engineering addresses biological barriers and enhances antitumor efficacy.

Intelligent responsive nanocarriers integrate dynamic functionalities that sense and adapt to tumor-specific cues, enabling on-demand drug release, morphological transformations, or activation of prodrugs [28]. Hence, addressing key limitations like premature leakage (reduced from 20–30% to < 5%) and poor penetration (improved by 3–5-fold through size/charge switching), with endogenous stimuli including pH gradients (extracellular 6.5–7.2 vs. endosomal 4.5–5.5), redox potentials (glutathione 2–10 mM intracellular vs. 2–20 μM extracellular), enzymes (e.g., MMPs overexpressed 10–100-fold in tumors), and hypoxia (oxygen < 1% vs. 5–10% normal), while exogenous triggers like ultrasound (frequencies 1–3 MHz inducing cavitation for 50–80% release) or near-infrared light (wavelengths 650–900 nm for photothermal activation) provide spatiotemporal control [29]. pH-responsive systems, such as those with hydrazone bonds (stable at pH 7.4, hydrolyzing at pH 5.0 with 70–90% release in 24 hours), exemplify this, as in doxorubicin-loaded poly(histidine) micelles that exhibit 4-fold higher cytotoxicity in acidic MCF-7 cells (IC50 0.2 μg/mL vs. 0.8 μg/mL neutral), corroborated by in vivo studies showing 85% tumor regression in xenografts versus 40% for non-responsive carriers [26]. Redox-sensitive disulfide linkages cleave in glutathione-rich cytosol, facilitating burst release (60–80% within 2 hours) and overcoming endosomal barriers, as demonstrated by siRNA-nanoparticles silencing BCL-2 with 90% efficiency in resistant ovarian cancer models [30]. Enzyme-triggered nanocarriers, incorporating cathepsin B-cleavable peptides, achieve site-specific activation, with quantitative assays revealing 5–10-fold higher payload delivery in protease-high tumors; for instance, hyaluronidase-degradable hyaluronic acid shells unmask targeting ligands, enhancing uptake by 3-fold in CD44-overexpressing cancers [31]. Quantitative characteristics of various stimuli-responsive systems—including their trigger conditions, mechanisms, and release kinetics—are summarized in Table 1.

Hypoxia-responsive azobenzene groups disassemble under low oxygen, releasing nitroimidazole-sensitized radiosensitizers that improve radiotherapy efficacy by 2–3-fold (tumor volume reduction 70% vs. 30%) [32]. Exogenous stimuli, such as magnetic hyperthermia with iron oxide cores (heating to 42–45°C for 30 minutes, inducing 80% apoptosis), synergize with chemotherapy, as in clinical trials of ThermoDox^® (thermosensitive liposomes) showing 2-fold complete response rates in hepatocellular carcinoma when combined with radiofrequency ablation [33]. Hybrid multi-stimuli systems, like pH/redox dual-responsive dendrimers, exhibit synergistic release kinetics (95% cumulative release vs. 50% single-stimulus), mitigating resistance in heterogeneous tumors [34]. Despite promising preclinical data, challenges include stimulus variability (e.g., pH fluctuations 0.5–1 unit interpatient) and potential off-target activation (e.g., in inflamed tissues), necessitating rigorous pharmacokinetic modeling and imaging-guided validation to ensure 80–90% specificity, paving the way for personalized regimens that could elevate response rates from 20–30% to 50–70% in advanced cancers [35]. Figure 3 demonstrates the concept of stimuli-responsive nanocarriers that release therapeutic agents in response to endogenous tumor microenvironmental cues such as pH, redox potential, and enzyme activity.

The biological performance of nanocarriers is shaped not only by their physicochemical attributes but also by their interaction with complex biological interfaces [48]. Over the past two decades, significant attention has been directed toward optimizing properties such as mucoadhesiveness, mucopenetration, cytoadhesiveness, and tumor repressiveness, each representing a distinct interface-driven function influencing therapeutic accumulation, retention, and cellular uptake [49]. Mucoadhesiveness refers to the ability of nanocarriers to adhere to mucosal surfaces through electrostatic interactions, hydrogen bonding, hydrophobic interactions, or polymer chain entanglement [50]. Historically, this property emerged from early bioadhesive polymer research in the 1980s, where chitosan, carbopol, and poly(acrylic acid) were first identified as mucoadhesive enhancers for drug formulations. In cancer targeting—particularly gastrointestinal, pulmonary, and cervical cancers—mucoadhesive nanocarriers prolong residence time at mucosal tumor interfaces, improving localized drug concentration. For example, chitosan-coated nanoparticles have demonstrated enhanced retention and improved cytotoxicity in colorectal tumor models [51, 52].

Unlike mucoadhesiveness, mucopenetration focuses on the ability of nanocarriers to rapidly diffuse through the mucus mesh without getting trapped [53]. This concept gained prominence in the early 2000s with the advent of PEGylated and zwitterionic surfaces capable of minimizing hydrophobic and electrostatic interactions with mucin fibers. Mucopenetrating nanoparticles (MPPs) improve drug delivery to tumors shielded by dense mucus barriers, such as pancreatic and lung cancers. PEG-coated PLGA nanoparticles, for example, penetrate mucin layers up to 10-fold more effectively than uncoated systems, ensuring deeper tumor access and more uniform drug distribution [54, 55]. Cytoadhesiveness involves the intentional design of nanocarriers to adhere to cancer cell membranes, exploiting overexpressed receptors, altered surface charge, or glycan patterns. Historically driven by the rise of cell-targeting ligands in the late 1990s—such as RGD peptides, folate, and antibodies—cytoadhesive systems enhance receptor-mediated uptake and intracellular accumulation. Increased surface binding leads to more efficient endocytosis and reduced off-target clearance [56]. For instance, RGD-decorated liposomes show 4–6-fold increased internalization in integrin-overexpressing tumors compared to non-targeted formulations. Tumor repressiveness describes the intrinsic ability of certain nanocarriers to suppress tumor growth independent of their drug cargo, a concept emerging over the last decade [57]. Materials such as cerium oxide nanoparticles, iron oxide nanoparticles, and specific carbon nanostructures can modulate oxidative stress, disrupt mitochondrial function, or trigger immunogenic responses that inhibit tumor proliferation. Additionally, cell membrane-coated nanoparticles can mimic immune cells, reprogramming the tumor microenvironment toward antitumor activity [58]. For example, neutrophil-membrane-coated nanocarriers can neutralize inflammatory cytokines and suppress tumor-promoting signaling pathways.

Nanocarrier-based antitumor therapies have progressed significantly in clinical settings, with over 50 formulations approved and hundreds in trials, demonstrating improved pharmacokinetics (e.g., AUC increases of 2–10-fold), reduced toxicities (e.g., neutropenia incidence halved), and enhanced efficacy (e.g., response rates 20–50% higher) in malignancies like breast, lung, and pancreatic cancers, where passive-targeted liposomes such as Doxil^® (approved 1995) achieve 3–5 month gains in PFS for Kaposi’s sarcoma by exploiting EPR for 10–15% tumor accumulation while lowering cardiotoxicity risk from 20% to < 5% [59]. Active-targeted candidates like MM-302 (phase II, HER2-targeted doxorubicin liposomes) reported partial responses in 11% of anthracycline-pretreated breast cancer patients, with a median PFS of 7.6 months versus 3.5 months historical controls, though immunogenicity limited dosing [60]. In gene therapy, CALAA-01 (cyclodextrin-based siRNA nanoparticles, phase I) silenced RRM2 in melanoma with 21% tumor reduction at 0.6 mg/kg, confirming target engagement via RISC loading assays [61]. Combination trials, such as ThermoDox^® with radiofrequency ablation (phase III, hepatocellular carcinoma), yielded complete responses in 33% versus 12% controls, leveraging thermosensitive release (100% at 42°C) for 5-fold intratumoral doxorubicin [58]. Immunotherapy integrations, like mRNA-4157 lipid nanoparticles (LNPs) (phase II, melanoma), elicited CD8+ T-cell responses in 70% patients, with 25% objective responses when combined with pembrolizumab [62]. Quantitative pharmacodynamics from trials show nanocarriers extend drug exposure (t_1/2 20–50 hours vs. 1–4 hours free drug), with biodistribution imaging (e.g., 111In-labeled liposomes) revealing 5–10% hepatic uptake reduction via PEG [60]. Ongoing phase III trials, including NK105 (micellar paclitaxel) for gastric cancer, report hazard ratios of 0.7–0.8 for overall survival, while challenges like patient selection (EPR-high via imaging biomarkers) are addressed in adaptive designs [63]. Biomimetic approaches, such as erythrocyte-membrane-coated nanoparticles (phase I, solid tumors), prolong circulation to 72 hours and reduce immune clearance by 80%, potentiating 2-fold efficacy in resistant models [64]. Overall, clinical data affirm nanocarriers’ role in precision therapy, with meta-analyses indicating 15–25% survival benefits, though interpatient variability (EPR scores 0.3–1.7) necessitates stratified enrollment for optimal outcomes [65]. Recent clinical applications and outcomes of nanocarrier-based therapies are outlined in Table 3, summarizing phase progress, quantitative results, and therapeutic indications.

Notably, Onpattro^® (patisiran LNPs) and Givlaari^® (givosiran) have helped validate LNP platforms in regulatory pathways, paving the way for oncology-oriented LNP therapeutics. In 2022, the FDA approved Vyxeos^® liposomal CPX-351 for secondary acute myeloid leukemia subtypes, marking continued progress of ratio-controlled liposomal formulations [66]. More recently, mRNA-4157 (Moderna/ Merck LNP cancer vaccine) entered Phase III trials for melanoma, showing a 44% reduction in recurrence risk in combination with pembrolizumab [67]. Late-stage polymeric nanocarriers such as CRLX101 (polymeric camptothecin nanoconjugate) have reported durable disease stabilization in ovarian and renal cancers, while NK105 (polymeric paclitaxel micelle) continues Phase III investigation for gastric cancer with favorable toxicity reductions [68]. Meanwhile, exosome-based nanocarriers such as exoSTING™ (exosome-delivered STING agonist) have advanced into clinical evaluation for metastatic solid tumors, demonstrating the rise of biologically derived nanosystems [68]. These recent developments underscore the growing clinical maturity of nanocarrier technologies and highlight a new generation of platforms with improved stability, targeted biodistribution, and translational relevance.

Despite substantial advancements, nanocarrier-based antitumor therapy encounters multifaceted challenges including biological barriers like heterogeneous EPR (delivery efficiency 0.7–13.5% across patients), immune-mediated clearance (anti-PEG IgM reducing half-life by 50–70% after repeated doses), endosomal entrapment (releasing < 30% payload), and manufacturing scalability (yields 60–80%, polydispersity index > 0.2 risking variability), compounded by regulatory hurdles requiring rigorous characterization (e.g., ICH Q6B for impurities < 0.1%) and high costs (development $500–800 million), as evidenced by only 10% of preclinical candidates advancing to phase III [69]. Tumor microenvironment complexities, such as desmoplasia in pancreatic cancer impeding penetration (diffusion coefficients 10^–8–10^–9 cm²/s vs. 10^–6 in normal tissues) and hypoxia-induced resistance (HIF-1α upregulation decreasing efficacy by 2–3-fold), necessitate strategies like stroma-modulating adjuncts (e.g., hyaluronidase co-delivery increasing permeability by 4-fold) [70]. Toxicity concerns, including cytokine storms from inorganic carriers (e.g., silica inducing IL-6 elevations 5–10-fold) and long-term bioaccumulation (gold nanoparticles persisting > 6 months in liver), demand advanced safety profiling via multi-omics [71]. Future directions emphasize personalized nanomedicine, integrating AI-driven design (predicting EPR via machine learning with 85–95% accuracy) and companion diagnostics (e.g., 64Cu-labeled tracers for patient stratification, identifying high-EPR cohorts with 2-fold better responses) [72]. Hybrid intelligent systems, combining CRISPR-Cas9 with stimuli-responsive carriers (editing efficiency 40–60% in vivo), promise resistance reversal [e.g., multidrug resistance protein 1 (MDR1) knockout restoring sensitivity 5-fold] [73]. Theranostic integrations, like 89Zr-gold nanoparticles for PET-guided photothermal therapy (ablation efficiency > 90% at 1 W/cm²), enable real-time monitoring [74]. Sustainability focuses on biodegradable polymers (degradation < 3 months) and green synthesis (solvent-free yields > 90%) [75]. Collaborative efforts, as in the NCI Alliance, aim to accelerate translation, projecting 20–30 new approvals by 2030 and survival improvements of 10–20% in metastatic settings through multifaceted, adaptive therapies [76]. Emerging technologies, such as 3D-printed nanocarriers for customized dosing (precision ± 5% in drug loading), further address reproducibility issues [77]. Overcoming immune barriers through glycoengineering (reducing clearance by 60–80%) will enhance repeated dosing efficacy [78]. Ultimately, integrating big data analytics with nanocarrier development could boost clinical success rates from 10% to 30–40%, revolutionizing precision oncology [79].

The evolution of nanocarrier-based antitumor therapy reflects a clear paradigm shift from passive accumulation driven by the EPR effect to increasingly sophisticated systems designed for intelligent, stimuli-responsive drug delivery. Passive targeting laid the foundation for nanomedicine by exploiting tumor vascular abnormalities; however, its inherent variability and limited delivery efficiency revealed critical biological and clinical constraints. Active targeting strategies addressed some of these limitations by incorporating ligand-receptor interactions to improve cellular specificity and uptake. Yet even these approaches remain insufficient in overcoming the heterogeneity of tumor microenvironments and the multifactorial barriers to drug penetration, distribution, and retention.

The emergence of intelligent nanocarriers represents the next frontier in precision oncology, integrating endogenous and exogenous stimuli—such as pH, redox gradients, enzymatic activity, hypoxia, temperature, and light—to enable spatiotemporally controlled drug release. These systems offer the potential to minimize off-target exposure, enhance intratumoral drug activation, and improve therapeutic indices across diverse tumor phenotypes. Furthermore, biologically informed properties such as mucoadhesiveness, mucopenetration, cytoadhesiveness, and tumor-repressive behavior expand the functional versatility of nanocarriers within complex tissues.

Despite these advances, major bottlenecks continue to impede clinical translation. The heterogeneity of the EPR effect in patients, challenges associated with large-scale manufacturing and reproducibility, limited predictability of tumor-specific stimuli, and incomplete understanding of long-term biocompatibility remain significant obstacles. Regulatory pathways for advanced nanocarriers also require clearer guidelines, particularly for multifunctional platforms with combined targeting, imaging, and therapeutic capabilities. Robust pharmacokinetic-pharmacodynamic modeling, standardized characterization protocols, and harmonized preclinical-clinical evaluation frameworks are essential to bridge current gaps.

Looking forward, next-generation nanocarrier systems must integrate adaptive, multi-responsive architectures, real-time biological feedback (including AI-assisted design and digital biomarker integration), and improved biomimetic features to achieve clinically meaningful precision. By uniting material innovation with tumor biology, computational modeling, and translational engineering, intelligent nanocarriers hold the promise of delivering truly personalized and effective cancer therapies. Continued interdisciplinary collaboration will be critical to advancing these technologies from conceptual development toward routine clinical application.